Cargando…
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Context: Patients with B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) are at increased risk of morbidity and mortality from SARS-CoV-2 infection. Anti-SARS-CoV-2 vaccination is highly recommended for these patients but their antibody responses after the initial vaccination se...
Autores principales: | Chang, Andres, Lai, Lilin, Akhtar, Akil, Linderman, Susanne, Orellana-Noia, Victor, Saini, Manpreet, Valanparambil, Rajesh, Blum, Kristie, Allen, Pamela, Lechowicz, Mary, Romancik, Jason, Ayers, Amy, O'Leary, Colin, Churnetski, Michael, Kives, Melissa, Nooka, Ajay, Koff, Jean, Dhodapkar, Madhav, Suthar, Mehul, Cohen, Jonathon, Ahmed, Rafi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489239/ http://dx.doi.org/10.1016/S2152-2650(22)01352-0 |
Ejemplares similares
-
Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022) -
CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022) -
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022) -
CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022) -
CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)